PDL BioPharma is in the biotechnology industry and trades as part of the healthcare sector. The company CEO is Dominique Monnet. PDL BioPharma Inc is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing value of its patent.



Previous Intraday Performance:

The PDLI shares had a previous change of -6.23% which opened at 3.70 and closed at 3.46. It moved to an intraday high of 3.70 and a low of 3.43.

PR Newswire:  PDL BioPharma to Hold Annual Meeting of Stockholders on June 20, 2019

Historical Performance:

Over the last five trading days, PDLI shares returned -9.19% and in the past 30 trading days it returned -3.89%. Over three months, it changed 8.81%. In one year it has changed 14.95% and within that year its 52-week high was 3.89 and its 52-week low was 2.25. PDLI stock is 53.78% above its 52 Week Low.

Our calculations result in a 200 day moving average of 2.91 and a 50 day moving average of 3.59. Right now, PDLI stock is trading 19.05% above its 200 day moving average.

PR Newswire:  PDL BioPharma to Hold Annual Meeting of Stockholders on June 20, 2019

Liquidity:

The company has a market cap of $443.3m with 128.1m shares outstanding and a float of 121.1m shares. Trading volume was 2,038,451 shares and has experienced an average volume of 1,509,255 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for PDL BioPharma was -0.46 which ended on 31st of December 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is 0.08. The trailing twelve month EPS is 0.35, which comes to a trailing twelve month PE of 9.89.

Base on our calculations, the intrinsic value per share is 1.23, which means it might overvalued by -180.98%

The next earnings report will be: 05-09-2019

The growth of the EPS is critical in understanding the current valuation of PDL BioPharma; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -15.30% over the last twelve months.



Indicators Also to Watch:

Based on the latest filings, there is 132.20% of institutional ownership.

I calculated the beta to be 0.57

SeekingAlpha:  Tracking Chase Coleman’s Tiger Global Portfolio – Q4 2018 Update

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -8.95%, return on assets is -6.39%, profit margin is -82.14%, price-to-sales is 5.64 and price-to-book is 0.65.

Company Score Card:

Results are out of six:
 3  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here